Intellia Therapeutics Inc (NASDAQ: NTLA) on Monday, plunged -4.56% from the previous trading day, before settling in for the closing price of $10.74. Within the past 52 weeks, NTLA’s price has moved between $5.90 and $28.18.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -20.04% over the last five years. The company achieved an average annual earnings per share of 20.55%. With a float of $97.42 million, this company’s outstanding shares have now reached $103.54 million.
The firm has a total of 403 workers. Let’s measure their productivity. In terms of profitability, gross margin is 88.67%, operating margin of -1187.36%, and the pretax margin is -1154.1%.
Intellia Therapeutics Inc (NTLA) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Intellia Therapeutics Inc is 5.95%, while institutional ownership is 92.31%. The most recent insider transaction that took place on Jul 01 ’25, was worth 10,036. In this transaction EVP, Chief Technical Officer of this company sold 1,022 shares at a rate of $9.82, taking the stock ownership to the 95,369 shares. Before that another transaction happened on Jul 02 ’25, when Company’s VP, Chief Accounting Officer sold 2,503 for $9.95, making the entire transaction worth $24,905. This insider now owns 57,137 shares in total.
Intellia Therapeutics Inc (NTLA) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 20.55% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 31.18% during the next five years compared to -20.04% drop over the previous five years of trading.
Intellia Therapeutics Inc (NASDAQ: NTLA) Trading Performance Indicators
Intellia Therapeutics Inc (NTLA) is currently performing well based on its current performance indicators. A quick ratio of 4.90 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 23.30.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.23, a number that is poised to hit -1.03 in the next quarter and is forecasted to reach -3.86 in one year’s time.
Technical Analysis of Intellia Therapeutics Inc (NTLA)
Analysing the last 5-days average volume posted by the [Intellia Therapeutics Inc, NTLA], we can find that recorded value of 4.39 million was better than the volume posted last year of 3.92 million. As of the previous 9 days, the stock’s Stochastic %D was 76.52%.
During the past 100 days, Intellia Therapeutics Inc’s (NTLA) raw stochastic average was set at 62.68%, which indicates a significant decrease from 70.77% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 62.56% in the past 14 days, which was lower than the 93.34% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.72, while its 200-day Moving Average is $11.86. Now, the first resistance to watch is $10.66. This is followed by the second major resistance level at $11.06. The third major resistance level sits at $11.30. If the price goes on to break the first support level at $10.01, it is likely to go to the next support level at $9.78. Now, if the price goes above the second support level, the third support stands at $9.37.
Intellia Therapeutics Inc (NASDAQ: NTLA) Key Stats
Market capitalization of the company is 1.06 billion based on 103,583K outstanding shares. Right now, sales total 57,880 K and income totals -519,020 K. The company made 16,630 K in profit during its latest quarter, and -114,330 K in sales during its previous quarter.
